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Abstract 
Cross-sectional studies show that higher blood concentrations of inflammatory markers tend to be 
more common in frail older people but longitudinal evidence that these inflammatory markers are 
risk factors for frailty is sparse and inconsistent.  We investigated the prospective relation between 
baseline concentrations of the inflammatory markers C-reactive protein and fibrinogen and risk of 
incident frailty in 2146 men and women aged 60 to over 90 years from the English Longitudinal 
Study of Ageing.  The relationship between C-reactive protein and fibrinogen and risk of incident 
frailty differed significantly by sex (p for interaction terms <0.05). In age-adjusted logistic regression 
analyses, for a standard deviation increase in c-reactive protein or fibrinogen odds ratios (95% 
confidence intervals) for incident frailty in women were 1.69 (1.32, 2.17) and 1.39 (1.12, 1.72) 
respectively.  Further adjustment for other potential confounding factors attenuated both these 
estimates.  For an SD increase in CRP and fibrinogen the fully-adjusted odds ratio (95% confidence 
interval) for incident frailty in women was 1.27 (0.96, 1.69 and 1.31 (1.04, 1.67) respectively. Having 
a high concentration of both inflammatory markers was more strongly predictive of incident frailty 
than having a high concentration of either marker alone.   In men, there were no significant 
associations between any of the inflammatory markers and risk of incident frailty.   High 
concentrations of the inflammatory markers C-reactive protein and fibrinogen are more strongly 
predictive of incident frailty in women than in men.  Further research is needed to understand the 
mechanisms underlying this sex difference. 
Key words: frailty, inflammation, C-reactive protein, fibrinogen, longitudinal study 
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INTRODUCTION 
Frailty is a clinically recognizable syndrome observed in older people whose core feature is an 
increased vulnerability to stressors due to impairments in multiple, inter-related systems, decreased 
physiological reserves and a decline in the ability to maintain homeostasis (Bergman et al. 2007;Fried 
et al. 2001).   It is common (Syddall et al. 2010) and has numerous adverse consequences, including 
disability, falls, morbidity, hospitalization, institutionalization and death.   At present there is no 
universally accepted model or definition of frailty (Bergman et al. 2007), but it is generally agreed 
that its causes are complex and likely to involve both biological and psychosocial mechanisms 
(Walston et al. 2006;Rockwood et al. 1994).  
 
Linda Fried and John Walston hypothesized several years ago that inflammation, coupled with 
neuroendocrine dysregulation and sarcopenia, might underlie the onset of frailty (Fried and Walston 
1998) but as yet empirical evidence for this is limited.  Although several cross-sectional studies—
primarily in women—have reported higher blood concentrations of various inflammatory or 
coagulation markers such as C-reactive protein (CRP), interleukin-6 (IL-6), factor VIII and D-dimer 
in older people who meet the criteria for physical frailty that Fried et al devised (Bandeen-Roche et 
al. 2006), the design of these studies makes it impossible to establish whether inflammation precedes 
or follows the development of frailty (Collerton et al. 2012;Walston et al. 2002;Leng et al. 
2007;Hubbard et al. 2009;Schmaltz et al. 2005). Longitudinal evidence on whether such biomarkers 
are predictive of incident frailty in men and women is sparse and inconsistent.  Four prospective 
studies have examined the link between various inflammatory or coagulation markers and 
subsequent frailty to date. Of these, two--based on men and women from the Cardiovascular Health 
Study and the Longitudinal Ageing Study Amsterdam respectively--found significant associations 
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between raised concentrations of CRP at baseline and increased risk of incident frailty at follow-up, 
but raised levels of IL-6 were not predictive of increased risk (Barzilay et al. 2007;Puts et al. 2005). 
In the Hertfordshire Ageing Study, higher levels of range of immune-endocrine markers, including 
differential white cell counts, were associated with increased risk of later frailty in both sexes, 
although no association was found between CRP levels and frailty risk (Baylis et al. 2012). A fourth 
study, based on the Women’s Health Initiative, found that higher D-dimer and tissue plasminogen 
activator (t-PAS) were associated with higher risk of incident frailty, but neither CRP, IL-6, factor 
VIII or fibrinogen were linked with frailty risk (Reiner et al. 2009). There is a need for more 
longitudinal studies, particularly in men, to establish which inflammatory or coagulation markers are 
predictive of incident frailty and whether these associations are the same in both sexes.   
 
The English Longitudinal Study of Ageing (ELSA) is a large population-based sample of older men 
and women.  We used these data to investigate the prospective relation between the inflammatory 
markers, CRP, fibrinogen and ferritin and risk of incident physical frailty in men and women aged 60 
to over 90 years. 
 
METHODS 
Participants 
The data for this study come from the English Longitudinal Study of Ageing (ELSA).  The sample 
for ELSA was based on people aged ≥50 years who had participated in the Health Survey for 
England in 1998, 1999 or 2001 (Marmot et al. 2011;Steptoe et al. 2012).  It was drawn by postcode 
sector, stratified by health authority and proportion of households in non-manual socioeconomic 
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groups. 11,392 people participated in Wave 1 in 2002-3.  At Wave 2 in 2004-5 and at Wave 4 in 
2008-9 participants who completed the main interview were invited to have a visit from a nurse that 
included measurements of physical function, anthropometry and blood sampling.  Ethical approval 
was obtained from the Multicentre Research and Ethics Committee. Participants gave written 
informed consent.   
 
Measures 
 
Maximum handgrip strength was measured three times on each side using a dynamometer; the best 
of these measurements was used for analysis.   Height and weight were measured with a portable 
stadiometer and electronic scales respectively. Body mass index (BMI) was calculated as weight (in 
kilograms)/height (in metres)2 .  Gait speed was assessed in participants aged 60 and over by 
measuring the time taken to walk a distance of 8 feet at usual pace; the timed walk was repeated and 
the mean of the two measurements was calculated.  Participants responded to three questions about 
the frequency with which they did vigorous, moderate or mild exercise.  We ranked the 
combinations of responses to these questions according to the amount and intensity of exercise 
involved to provide an estimate of usual physical activity.  Symptoms of depression were assessed 
using the eight-item version of the Center for Epidemiologic Studies Depression Scale (CES-
D)(Steffick and The HRS working group 2000).  We used these data, together with information on 
participants’ weight at the initial survey, to derive an indicator of physical frailty at Wave 2 and at 
Wave 4 in men and women aged ≥60 years using the Fried criteria (Fried et al. 2001). These criteria 
define physical frailty as the presence of three or more of the following: unintentional weight loss, 
weakness, self-reported exhaustion, slow walking speed and low physical activity.   We 
operationalized these criteria using definitions very similar to those used in the original phenotype of 
frailty studies (Bandeen-Roche et al. 2006;Fried et al. 2001): weight loss was defined as either loss of 
6 
 
≥10% of body weight since the initial survey (for frailty at Wave 2) or since Wave 2 (for frailty at 
Wave 4), or current BMI <18.5 kg/m2; weakness was defined as maximum grip strength in the 
lowest 20% of the distribution, after taking sex and BMI into account; exhaustion was considered 
present if the participant gave a positive response to either of the CES-D questions ‘Felt that 
everything I did was an effort in the last week’ or ‘Could not get going in the last week’; slow 
walking speed was defined as a walking speed in the lowest 20% of the distribution, after taking 
account of sex and height; and low physical activity was defined as physical activity in the lowest sex-
specific 20% of the distribution. 
 
Participants were asked whether a doctor had ever told them that they had any of the following 
conditions: high blood pressure/hypertension, angina, heart attack, congestive heart failure, diabetes 
or high blood sugar, a stroke, chronic lung disease, arthritis or rheumatism, or cancer.  For the 
purposes of these analyses, we created a single variable to indicate history of cardiovascular disease 
from the variables on angina, heart attack, congestive heart failure and stroke. 
 
Cognitive function was assessed using tests of immediate and delayed verbal memory (recall of 10 
aurally-presented nouns), prospective memory (remembering to do a specific task), verbal (semantic) 
fluency (naming as many animals as possible in 60 seconds), and attention (letter cancellation 
task).(Marmot et al. 2011)  A total cognitive function score was calculated by summing scores on 
these tests.  Socioeconomic status was indexed by total household wealth, including savings and 
investments, value of any property or business assets, net of debt, excluding pension assets. 
Household wealth has been identified as the most accurate indicator of long-term socioeconomic 
circumstances in ELSA (Banks et al. 2003).  
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Blood samples were taken from all participants except those who were not willing to give written 
consent, those with clotting or bleeding disorders and those taking anti-coagulant drugs.  Fasting 
samples (defined as no food or drink except water for the past 5 hours) were taken where possible 
(67% of participants).  Samples were assayed for C-reactive protein and fibrinogen at the Royal 
Victoria Infirmary, Newcastle-upon-Tyne, UK. Detailed information on the technicalities of the 
blood analysis, the internal quality control, and the external quality assessment for the laboratory that 
carried it out are given in the 2004 Health Survey for England technical report as both the Health 
Survey for England and HSE and ELSA used the same laboratory, and the same guidelines and 
protocols for blood analysis.(Graig et al. 2006) 
 
Analytical sample 
Of the 5918 study members aged ≥60 years who were interviewed at Wave 2 in 2004-5, 5377 agreed 
to be visited by a nurse (91%) and 4571 (77%) agreed to give a blood sample.  Of these 4571 people, 
2168 (47%) were interviewed and visited by a nurse at Wave 4 in 2008-9. The present analysis is 
based on 2146 people who had complete data on baseline covariates at Wave 2 and frailty at Wave 4 
and who were not frail at baseline.  
 
 Statistical analysis 
The distribution of blood concentrations of CRP and fibrinogen was skewed and was transformed 
to normality using logarithms.  We used the t-test and chi-square test to examine differences in 
baseline characteristics between men and women according to the presence of incident frailty at 
follow up. We used logistic regression to examine the relation between each inflammatory marker 
and risk of incident frailty in men and women separately.  Initially we examined the unadjusted risk 
of incident frailty according to thirds of the distribution of CRP and fibrinogen, using these variables 
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in their original untransformed state.  Having established that there was no indication that the 
associations were non-linear, we then examined risk of incident frailty according to a standard 
deviation (SD) increase in log CRP and log fibrinogen, controlling for potentially confounding 
factors (age, household wealth, smoking status, BMI, depressive symptom score, cognitive function, 
history of cardiovascular disease, diabetes, hypertension, chronic lung disease, arthritis, or cancer, 
and number of frailty criteria present at baseline). All analyses were weighted to account for non-
response and the complex survey design.  Finally, we examined whether the risk of incident frailty 
associated with the combination of CRP and fibrinogen was greater than the risk associated with 
each inflammatory marker individually.  For this analysis—which was carried out in women only--we 
divided participants into four categories: those in the upper third of the distribution for both 
inflammatory markers, those in the upper third for CRP but not fibrinogen, those in the upper third 
for fibrinogen but not CRP, and the reference category of those who were not in the upper third for 
either marker.  
 
Results 
Table 1 shows the baseline characteristics of the 2146 men and women in the study according to 
whether they became frail during the follow-up period.    The weighted percentage of men and 
women who became frail during follow-up was 11% and 16% respectively.  In both men and 
women, incident cases of frailty tended to be older, to have poorer cognitive function, to have a 
history of diabetes, arthritis and chronic lung disease, and to meet more of Fried’s criteria for frailty 
at baseline.  In both sexes, incident frailty occurred more commonly in those who were in the lowest 
quintile for household wealth at baseline, but lack of wealth was much more strongly predictive of 
incident frailty in women than in men; in men the relation was of borderline statistical significance 
only. In women only, incident cases of frailty were associated with being more depressed, having a 
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higher BMI, having a history of cardiovascular disease and hypertension, and having higher blood 
concentrations of CRP and fibrinogen at baseline.  
 
Preliminary analyses showed that the relationships between baseline concentrations of CRP and 
fibrinogen and risk of incident frailty differed significantly between the sexes (p for interaction terms 
both<0.05).  Logistic regression analyses of frailty risk were therefore carried out in men and women 
separately. 
 
Figure 1a & b shows unadjusted odds ratios for incident frailty according to thirds of the 
distribution of concentrations of CRP and fibrinogen in men and women using the lowest third as 
the reference category.  In men there were no significant linear trends between concentrations of 
either inflammatory marker and risk of incident frailty. In women, risk of incident frailty rose with 
increasing concentrations of both CRP and fibrinogen (p for linear trend<0.0001). 
 
As there was no indication that the relationships between inflammatory markers and risk of incident 
frailty were non-linear, we examined risk of frailty for a standard deviation increase in CRP and 
fibrinogen to give us greater statistical power.  Table 2 shows adjusted odds ratios from these 
analyses.  Results are shown adjusted first for age and then with further adjustment for the other 
potential confounding variables measured at baseline, household wealth, depressive symptoms, 
cognitive function, body mass index, smoking, number of frailty criteria present, and history of 
cardiovascular disease, diabetes, hypertension, chronic lung disease, arthritis and cancer.  In men, 
there were no significant associations between the inflammatory markers and risk of incident frailty 
in age-adjusted analyses.  Further adjustment for the potential confounding variables had little effect 
on these estimates. In women, in models adjusting for age alone there were significant associations 
10 
 
between raised concentrations of CRP and fibrinogen at baseline and risk of incident frailty.  For an 
SD increase in CRP and fibrinogen the age-adjusted odds ratio (95% confidence interval) for 
incident frailty was 1.69 (1.32, 2.17) and 1.39 (1.12, 1.72) respectively.  Further adjustment for other 
potential confounding factors attenuated both these estimates.  For an SD increase in CRP and 
fibrinogen the fully-adjusted odds ratio (95% confidence interval) for incident frailty was 1.27 (0.96, 
1.69) (p=0.09) and 1.31 (1.04, 1.67) (p=0.03) respectively.   
 
We repeated these multivariate analyses to examine risk of incident frailty according to thirds of the 
distribution of CRP and fibrinogen.  In men, compared to those in the lowest third of the 
distribution of CRP, the fully-adjusted odds ratios (95% confidence interval) for incident frailty for 
those in the middle and top thirds of the distribution were 1.20 (0.63, 2.50) and 0.94 (0.49, 1.80) 
respectively; the equivalent figures for those in the middle and top thirds of the distribution of 
fibrinogen compared to those in the lowest third were 1.30 (0.66, 2.62) and 0.90 (0.44, 1.84) 
respectively. In women, those in the top third of the distribution of either CRP or fibrinogen had an 
increased risk of incident frailty compared to those in the bottom third, but these associations did 
not reach statistical significance: the fully-adjusted odds ratios (95% confidence interval) for incident 
frailty for those in the middle and top thirds of the CRP distribution were 0.81 (0.45, 1.44) and 1.41 
(0.80, .2.49) respectively;  the equivalent figures for those in the middle and top thirds of the 
distribution of fibrinogen compared to those in the lowest third were 0.99 (0.63, 1.62) and 1.32 
(0.81, 2.17) respectively.     
  
Finally, we examined whether women who had high blood concentrations of both fibrinogen and 
CRP (defined here as being in the top third of the distribution of both these inflammatory markers) 
had a greater risk of incident frailty than those who had high blood concentrations of either of these 
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markers alone (defined as being in the top third of either fibrinogen or CRP only).  Results of this 
analysis are shown in Table 3.  Risk of incident frailty was greatest in women with high 
concentrations of both inflammatory markers. Having high concentrations of either marker alone 
was not associated with increased risk, although it is important to note that confidence intervals 
around these latter estimates were wide and numbers of cases of frailty in the group with high 
concentrations of fibrinogen alone were small.  
 
 
 
Discussion 
 
In this large longitudinal study of people aged 60 to over 90 years, higher baseline concentrations of 
the inflammatory markers CRP and fibrinogen were each separately associated with an increased risk 
of incident frailty in women. After adjustment for potential confounding factors, the association 
between CRP and risk of incident frailty was attenuated such that it became of borderline statistical 
significance, but that between fibrinogen concentration risk of incident frailty remained significant.  
Having a high concentration of both inflammatory markers was more strongly predictive of incident 
frailty than having a high concentration of either marker alone. In men, by contrast, there was no 
evidence that higher concentrations of any of these inflammatory markers were associated with 
increased risk. 
 
Existing evidence on whether the relationship between inflammatory markers and risk of frailty is 
the same in men and women is sparse. Of the three previous prospective studies that have examined 
the link between inflammation and risk of frailty in mixed sex populations, all have analysed men 
and women together (Puts et al. 2005;Baylis et al. 2012;Barzilay et al. 2007). One of these studies 
reported that associations between a range of immune-endocrine markers—among them differential 
white cell counts--and later risk of frailty were similar in men and women (Baylis et al. 2012).  In 
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contrast to the present study, no association was found between CRP concentration and subsequent 
frailty in either sex (Baylis et al. 2012).  Another study reported that the association found between 
CRP levels, categorised into three groups, and subsequent incident frailty did not differ significantly 
between the sexes;13 whether treating CRP as a categorical rather than continuous variable in this 
analysis affected the authors’ ability to detect any interaction by sex is uncertain.  Our finding that 
the relationship between the inflammatory factors CRP and fibrinogen and risk of incident frailty 
was markedly stronger in women is therefore novel. However, previous studies have found evidence 
of a sex difference in associations between inflammatory markers and outcomes other than frailty.  
For instance, concentrations of CRP or fibrinogen have been much more strongly associated with 
type 2 diabetes (Thorand et al. 2007;Lee et al. 2009), the metabolic syndrome (Rudnicka et al. 2011), 
blood pressure (Pruijm et al. 2012) and mortality (Jenny et al. 2007) in women than in men.   
 
The reasons why inflammatory markers were more strongly associated with frailty in women than in 
men in our study are unclear.  One potential explanation may lie in differences in distribution of 
body fat.  Women’s tendency to have more adipose tissue than men results in greater hepatic 
production of CRP.  As a result associations between CRP and body size or fat mass tend to be 
stronger in women than in men (Khera et al. 2009;Bowles et al. 2003;Thorand et al. 2006).   In the 
present study correlations between CRP and BMI were markedly greater in women than in men 
(r=0.42 vs r=0.22); a similar difference was observed in the case of correlations between fibrinogen 
and BMI (r=0.19 vs r=0.06). Obesity-triggered inflammation could have a greater influence on the 
onset of frailty in women.  In this study high BMI was associated with an increased risk of incident 
frailty in women, but not in men.  We examined whether BMI accounted for the interaction between 
sex and inflammatory factors (data not shown).  Adjustment for BMI weakened the interaction term 
but it remained statistically significant.  We lacked specific data on fat mass so were not able to 
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investigate what role it might play in the interaction by sex.   Another possibility may be that 
endogenous sex hormone levels or HPA axis hormones such as dehydroepiandosterone interact 
with inflammatory markers to influence risk of frailty (Voznesensky et al. 2009), but no data were 
available to explore this.  There are indications that lower levels of physical activity may be more 
strongly linked to poorer physical function in women than in men (Martin et al. 2008) but, no our 
knowledge, there have been no reports of a sex difference in the inverse association between 
physical activity and levels of inflammatory markers (Klenk et al. 2012;Rothenbacher et al. 2003) so 
this is unlikely to explain our results.  Our findings could perhaps have arisen if men with high levels 
of inflammatory markers were less likely to take part in the follow-up survey due to death or non-
response than women with high levels of these markers, but we found no evidence of this.  
However, it is important to note that the confidence intervals around the multivariate-adjusted 
estimates in our sample of 988 men were very wide.  For a SD increase in baseline CRP in men, for 
instance, our results were statistically compatible with a reduction of as much as 53% in the risk of 
incident frailty or with an increase in risk of up to 29%.  Further large studies specifically in men are 
needed to investigate the nature of the relation between inflammatory markers and risk of incident 
frailty in this group. 
 
The strengths of our study include the large sample size, the fact that it is representative of the 
community-dwelling English population aged 60 and over (Taylor et al. 2003), and our use of a 
prospective study design in which we assessed incident cases of frailty that occurred after the 
measurement of inflammatory markers. There are also some weaknesses.  Firstly, not all the 
participants in the baseline survey gave a blood sample (77% of those interviewed); non-responders 
to the blood sample tended to be older and in poorer health.  However, all analyses have been 
weighted to reduce any potential bias arising from differential non-response. Secondly, there was 
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limited characterisation of inflammatory markers or body composition at baseline and no 
information on the endocrine axis.   Thirdly, it is possible that results of our multivariate analyses 
might be affected by residual confounding as we lacked detailed data on the medications that 
participants were taking at baseline and on the severity of the specific chronic diseases that they 
reported; furthermore, information on the prevalence of such diseases may have been incomplete. 
 
In this prospective study of people aged 60 to over 90 years, higher concentrations of the 
inflammatory markers CRP and fibrinogen were predictive of incident frailty in women but not in 
men.  Future research needs to investigate the mechanisms underlying this sex difference. 
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Figure 1 a & b: Unadjusted odds ratios for incident frailty in men (a) and women (b) 
according to thirds of the distribution of blood concentrations of CRP and fibrinogen at 
baseline 
 
a) 
 
 
b)  
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Table 1:  Baseline characteristics of the men (n=988) and women (n=1158) in the study according to incident frailty at follow-up 
 
 Men    Women    
 Frail  
(n=80) 
Not frail 
(n=908) 
P value Frail 
(n=150) 
Not frail  
(n=1008) 
P value 
Age (yrs), mean (SE) 76.2 (1.17) 69.2 (0.24) <0.0001 76.7 (0.87) 69.7 (0.28) <0.0001 
Lowest quintile of wealth, (%) 21.1 13.1 0.09 34.3 17.0 <0.0001 
Current smoker, (%) 17.4 11.2 0.16 12.0 8.8 0.25 
History of cardiovascular disease, (%) 21.5 18.5 0.52 19.4 10.4 0.004 
History of diabetes, (%) 21.1 6.49 <0.0001 13.3 5.05 0.0003 
History of chronic lung disease, (%) 10.9 5.67 0.07 14.2 5.24 0.0002 
History of arthritis, (%) 39.1 27.1 0.03 69.9 42.0 <0.0001 
History of cancer, (%) 9.86 7.48 0.528 10.6 8.51 0.44 
History of hypertension, (%) 48.7 40.5 0.17 63.8 43.0 <0.0001 
No of frailty criteria present, mean (SE) 1.03 (0.09) 0.50 (0.03) <0.0001 1.13 (0.07) 0.46 (0.02) <0.0001 
Depressive symptom score ≥4, % 4.47 4.13 0.89 20.0 9.90 0.001 
Cognitive function, mean (SE) 24.8 (0.52) 28.3 (0.19) <0.0001 25.8 (0.53) 29.3 (0.21) <0.0001 
BMI, mean (SE) 27.0 (0.54) 27.1 (0.12) 0.37 28.9 (0.46) 27.4 (0.16) 0.002 
C-reactive protein (mg/l), geometric 
mean (SE) 
2.14 (1.13) 1.90 (1.03) 0.36 2.84 (1.09) 2.05 (1.03) 0.002 
Fibrinogen (g/l), geometric mean (SE) 3.12 (1.03) 3.09 (1.01) 0.85 3.36 (1.02) 3.18 (1.01) 0.01 
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Table 2: Adjusted odds ratios (95% CI) for incident frailty in men and women according to concentrations of CRP and 
fibrinogen at baseline 
 
Inflammatory marker Men Women 
OR (95% CI), 
adjusted for age 
OR (95% CI), fully 
adjusted2  
OR (95% CI), 
adjusted for age 
OR (95% CI), fully 
adjusted*  
C-reactive protein, per SD 0.98 (0.72, 1.32) 0.93 (0.66, 1.30) 1.69 (1.32, 2.17) 1.27 (0.96, 1.69) 
Fibrinogen, per SD 0.92 (0.70, 1.21) 0.89 (0.67, 1.18) 1.39 (1.12, 1.72) 1.31 (1.04, 1.67) 
1The SD of natural log C-reactive protein is 1.5 in men and women.  The SD of natural log fibrinogen is 0.21 in men 0.20 in women. 
2adjusted for age, household wealth, depressive symptoms, cognitive function, body mass index, smoking, number of frailty criteria present, 
and history of cardiovascular disease, diabetes, hypertension, chronic lung disease, arthritis and cancer.  
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Table 3: Adjusted odds ratios (95% CI) for incident frailty in women: comparing the effect of 
high fibrinogen alone, high CRP alone, or high fibrinogen and CRP combined.  
 
Inflammatory marker  No of 
cases/no at 
risk 
OR (95% CI), 
adjusted for age 
OR (95% CI), fully 
adjusted1  
Neither fibrinogen nor CRP in 
upper third of distribution 
60/635 1.0 1.0 
Only fibrinogen in upper third 
of distribution 
10/122 0.67 (0.32, 1.40 0.63 (0.28, 1.39) 
Only CRP in upper third of 
distribution 
31/174 1.93 (1.18, 3.17) 1.10 (0.62, 1.95) 
Both fibrinogen and CRP in 
upper third of distribution 
45/203 2.82 (1.80, 4.42) 1.89 (1.12, 3.21) 
2adjusted for age, household wealth, depressive symptoms, cognitive function, body mass index, 
smoking, number of frailty criteria present, and history of cardiovascular disease, diabetes, 
hypertension, chronic lung disease, arthritis and cancer.  
 
 
